New Rosuvastatin Analogs Design for Cardiovascular Disease through Receptor Based Drug Design Methods

Abstract

Rosuvastatin, is a member of the drug class of statins, used in combination with exercise, diet, and weight-loss to treat high cholesterol and related conditions, and to prevent cardiovascular disease.Rosuvastatin reduces levels of bad cholesterol and triglycerides in the blood. HMG-CoA reductase (3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, officially abbreviated HMGCR) is the rate-controlling enzyme (NADH-dependent, NADPH-dependent)of the mevalonate pathway, the metabolic pathway that produces cholesterol and other isoprenoids. Normally in mammalian cells this enzyme is suppressed by cholesterol derived from the internalization and degradation of low density lipoprotein (LDL) via the LDL receptor as well as oxidized species of cholesterol.the potential target protein for Cardiovascular Disease is HMG-CoA REDUCTASE and Rosuvastatin analogs are potential inhibitors for HMG CoA Reductase. New Rosuvastatin analogs will be developed through Receptor Based Drug Designing Methods including binding affinity Calculations. Binding Affinity Calculations will be performed through Genomics, proteomics, MolecularModeling, Protein 3D structural analysis and Molecular Docking Methods The best inhibitor for HMG CoA Reductase will be identified through binding affinity calculations